Latest Multiple drug resistance Stories
Hepatocellular carcinoma (HCC) responds poorly to chemotherapy owing to MDR.
DEERFIELD, Ill., May 3 /PRNewswire/ -- Antimicrobial resistance has emerged as a global health problem and is a major impediment in managing childhood infectious diseases.
The use of antibiotics to treat bacterial infections causes a continual and vicious cycle in which antibiotic treatment leads to the emergence and spread of resistant strains, forcing the use of additional drugs leading to further multi-drug resistance.
HAYWARD, Calif. and SHANGHAI, April 6 /PRNewswire/ -- MicuRx Pharmaceuticals, Inc., a biopharmaceutical company dedicated to the development of antibiotics to treat drug-resistant bacteria, and Cumencor Pharmaceuticals, Inc.
Two new tuberculosis studies by UT Southwestern Medical Center researchers provide good news and bad news about the bacterium that infects nearly a third of the world's population and a disease that kills nearly 2 million people each year.
Multidrug resistant bacteria such as Methicillin-resistant Staphylococcus aureus (MRSA) pose a major problem for patients, doctors, and the pharmaceutical industry.
A sudden worldwide increase in an antibiotic-resistant bacterium is cause for concern, according to a review in f1000 Medicine Reports.
Antibiotic resistance in the natural environment is rising despite tighter controls over our use of antibiotics in medicine and agriculture, Newcastle University scientists have found.
Scientists have identified a strain of antibiotic-resistant tuberculosis that thrives in the presence of rifampin, a front-line drug in the treatment of tuberculosis.
PARIS, December 23 /PRNewswire/ -- Novexel, a speciality pharmaceutical company focused on the discovery and development of novel antibiotics designed to overcome the significant global problem of microbial drug resistance, announces today that its shareholders have signed a definitive agreement whereby Novexel shall be acquired by AstraZeneca for a total cash consideration of up to $505 million, including contingent payments and the net cash position of the company at closing.
- The practice of two or more parties jointly purchasing all or part of a butchered cow and dividing the meat between them.